Imperial College London
Portrait Picture

Professor Martin Wilkins

Faculty of Medicine, National Heart & Lung Institute

Professor of Clinical Pharmacology
 
 
 
//

Contact

 

+44 (0)20 3313 6101m.wilkins Website

 
 
//

Assistant

 

Mrs Elizabeth O'Brien +44 (0)20 3313 6101

 
//

Location

 

NIHR Imperial Clinical Research FacilityICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Howard:2013:10.4103/2045-8932.109923,
author = {Howard, LSGE and Watson, GMJ and Wharton, J and Rhodes, CJ and Chan, K and Khengar, R and Robbins, PA and Kiely, DG and Condliffe, R and Elliott, CA and Pepke-Zaba, J and Sheares, K and Morrell, NW and Davies, R and Ashby, D and Gibbs, JSR and Wilkins, MR},
doi = {10.4103/2045-8932.109923},
journal = {Pulmonary Circulation},
pages = {100--107},
title = {Supplementation of iron in pulmonary hypertension: Rationale and design of a phase II clinical trial in idiopathic pulmonary arterial hypertension},
url = {http://dx.doi.org/10.4103/2045-8932.109923},
volume = {3},
year = {2013}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Our aim is to assess the safety and potential clinical benefit of intravenous iron (Ferinject) infusion in iron deficient patients with idiopathic pulmonary arterial hypertension (IPAH). Iron deficiency in the absence of anemia (1) is common in patients with IPAH; (2) is associated with inappropriately raised levels of hepcidin, the key regulator of iron homeostasis; and (3) correlates with disease severity and worse clinical outcomes. Oral iron absorption may be impeded by reduced absorption due to elevated hepcidin levels. The safety and benefits of parenteral iron replacement in IPAH are unknown. Supplementation of Iron in Pulmonary Hypertension (SIPHON) is a Phase II, multicenter, double-blind, randomized, placebo-controlled, crossover clinical trial of iron in IPAH. At least 60 patients will be randomized to intravenous ferric carboxymaltose (Ferinject) or saline placebo with a crossover point after 12 weeks of treatment. The primary outcome will be the change in resting pulmonary vascular resistance from baseline at 12 weeks, measured by cardiac catheterization. Secondary measures include resting and exercise hemodynamics and exercise performance from serial bicycle incremental and endurance cardiopulmonary exercise tests. Other secondary measurements include serum iron indices, 6-Minute Walk Distance, WHO functional class, quality of life score, N-terminal pro-brain natriuretic peptide (NT-proBNP), and cardiac anatomy and function from cardiac magnetic resonance. We propose that intravenous iron replacement will improve hemodynamics and clinical outcomes in IPAH. If the data supports a potentially useful therapeutic effect and suggest this drug is safe, the study will be used to power a Phase III study to address efficacy.
AU  - Howard,LSGE
AU  - Watson,GMJ
AU  - Wharton,J
AU  - Rhodes,CJ
AU  - Chan,K
AU  - Khengar,R
AU  - Robbins,PA
AU  - Kiely,DG
AU  - Condliffe,R
AU  - Elliott,CA
AU  - Pepke-Zaba,J
AU  - Sheares,K
AU  - Morrell,NW
AU  - Davies,R
AU  - Ashby,D
AU  - Gibbs,JSR
AU  - Wilkins,MR
DO  - 10.4103/2045-8932.109923
EP  - 107
PY  - 2013///
SN  - 2045-8940
SP  - 100
TI  - Supplementation of iron in pulmonary hypertension: Rationale and design of a phase II clinical trial in idiopathic pulmonary arterial hypertension
T2  - Pulmonary Circulation
UR  - http://dx.doi.org/10.4103/2045-8932.109923
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209981400013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://journals.sagepub.com/doi/10.4103/2045-8932.109923
UR  - http://hdl.handle.net/10044/1/82078
VL  - 3
ER  -
Download